Crystal Structures and Structure Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors

被引:122
|
作者
Tojo, Shingo [1 ]
Kohno, Tetsuya [1 ]
Tanaka, Tomoyuki [1 ]
Kamioka, Seiji [1 ]
Ota, Yosuke [1 ]
Ishii, Takayuki [1 ]
Kamimoto, Keiko [1 ]
Asano, Shigehiro [1 ]
Isobe, Yoshiaki [1 ]
机构
[1] Dainippon Sumitomo Pharma Co Ltd, Konohana Ku, Osaka 5540022, Japan
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2014年 / 5卷 / 10期
关键词
Indoleamine 2,3-dioxygenagse 1; crystal structure; induced fit; structure-based drug discovery; imidazothiazole; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN; TOLERANCE; DESIGN;
D O I
10.1021/ml500247w
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Indoleamine 2,3-dioxygenase 1 (IDO1) is considered as a promising target for the treatment of several diseases, including neurological disorders and cancer. We report here the crystal structures of two IDO1/IDO1 inhibitor complexes, one of which shows that Amg-1 is directly bound to the heme iron of IDO1 with a clear induced fit. We also describe the identification and preliminary optimization of imidazothiazole derivatives as novel IDO1 inhibitors. Using our crystal structure information and structure activity relationships (SAR) at the pocket-B of IDO I, we found a series of urea derivatives as potent IDO1 inhibitors and revealed that generation of an induced fit and the resulting interaction with Phe226 and Arg231 are essential for potent IDO1 inhibitory activity. The results of this study are very valuable for understanding the mechanism of IDOI activation, which is very important for structure-based drug design (SBDD) to discover potent IDO1 inhibitors.
引用
收藏
页码:1119 / 1123
页数:5
相关论文
共 50 条
  • [41] Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects in vivo
    Ge, Shushan
    Zhong, Haiqing
    Ma, Xuewei
    Zheng, Yingbo
    Zou, Yi
    Wang, Fang
    Wang, Yan
    Hu, Yue
    Li, Yuezhen
    Liu, Wen
    Guo, Wenjie
    Xu, Qiang
    Lai, Yisheng
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, 35 (01) : 1240 - 1257
  • [42] Advances in the discovery and development of selective heme-displacing IDO1 inhibitors
    Sun, Lijun
    EXPERT OPINION ON DRUG DISCOVERY, 2020, 15 (10) : 1223 - 1232
  • [43] Design, synthesis and biological evaluation of phenylsulfonamide-based IDO1 inhibitors
    Jin Shuanglong
    Wang Fang
    Zou Yi
    Wang Yan
    Hu Yue
    Guo Wenjie
    Xu Qiang
    Lai Yisheng
    JOURNAL OF CHINA PHARMACEUTICAL UNIVERSITY, 2018, 49 (01) : 34 - 38
  • [44] Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors
    Cui, Guonan
    Lai, Fangfang
    Wang, Xiaoyu
    Chen, Xiaoguang
    Xu, Bailing
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 188
  • [45] Binding properties of different categories of IDO1 inhibitors: a microscale thermophoresis study
    Greco, Francesco Antonio
    Coletti, Alice
    Custodi, Chiara
    Dolciami, Daniela
    Di Michele, Alessandro
    Carotti, Andrea
    Marinozzi, Maura
    Schlinck, Nina
    Macchiarulo, Antonio
    FUTURE MEDICINAL CHEMISTRY, 2017, 9 (12) : 1327 - 1338
  • [46] SAR towards indoline and 3-azaindoline classes of IDO1 inhibitors
    Yu, Wensheng
    Deng, Yongqi
    Hopkins, Brett
    Huang, Xianhai
    Sloman, David
    Zhang, Hongjun
    Li, Derun
    McGowan, Meredeth A.
    White, Catherine
    Pu, Qinglin
    Liu, Kun
    Fradera, Xavier
    Lesburg, Charles A.
    Martinot, Theo
    Doty, Amy
    Ferguson, Heidi
    Nickbarg, Elliott B.
    Cheng, Mangeng
    Geda, Prasanthi
    Song, Xuelei
    Smotrov, Nadya
    Abeywickrema, Pravien
    Andrews, Christine
    Chamberlin, Chad
    Mabrouk, Omar
    Curran, Patrick
    Richards, Matthew
    Saradjian, Peter
    Miller, J. Richard
    Knemeyer, Ian
    Otte, Karin
    Vincent, Stella
    Sciammetta, Nunzio
    Bennett, David Jonathan
    Han, Yongxin
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 47
  • [47] An updated patent review of IDO1 inhibitors for cancer (2018-2022)
    Wang, Peng-Fei
    Yang, Li-Qiang
    Shi, Zhao-Hang
    Li, Xue-Min
    Qiu, Han-Yue
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2022, 32 (11) : 1145 - 1159
  • [48] Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors
    Hou, Xi-xi
    Gong, Xiao-qing
    Mao, Long-fei
    Sun, Ge
    Yang, Jian-xue
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [49] Discovery and evolution of potent and selective heme-displacing IDO1 inhibitors
    McGowan, Meredeth
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [50] Synthesis, Docking and Biological Evaluation of a Novel Class of Imidazothiazoles as IDO1 Inhibitors
    Serafini, Marta
    Torre, Enza
    Aprile, Silvio
    Massarotti, Alberto
    Fallarini, Silvia
    Pirali, Tracey
    MOLECULES, 2019, 24 (10):